IQVIA CEO Sells Shares Worth $26.1 Million Amid Record Bookings
IQVIA Holdings Inc.'s CEO, Ari Bousbib, sold approximately 106,000 shares for a total of $26.1 million in an SEC Form 4 filing. The transaction involved the exercise and sale of stock appreciation rights expiring in February 2027 at a weighted average price of $245.51 per share. While Bousbib reduced his direct holdings by about 11%, he still retains significant ownership, including over 836,000 shares directly held and an additional 543,000 through the Orohena Trust. The sale occurred shortly after IQVIA reported a strong second-quarter performance with revenue rising to $4.37 billion—a year-over-year increase of 8.7%. The company also achieved record clinical bookings of $3.15 billion and saw adjusted earnings per share rise by 12.1% to $3.15. Analysts suggest the CEO's move was primarily a timing decision tied to expiring rights rather than an indication of his confidence in the stock. IQVIA remains well-positioned with a market capitalization of $38.8 billion and TTM revenue of $17.0 billion, serving pharmaceutical companies globally through its data analytics, technology platforms, and clinical research services.
Tickers: $IQV
Topics: executive sale IQVIA Holdings SEC Form 4